Year |
Citation |
Score |
2019 |
Walker I, Netherland J. Developing a Transformative Drug Policy Research Agenda in the United States Contemporary Drug Problems. 46: 3-21. DOI: 10.1177/0091450918811178 |
0.319 |
|
2017 |
Netherland J, Hansen H. White opioids: Pharmaceutical race and the war on drugs that wasn't. Biosocieties. 12: 217-238. PMID 28690668 DOI: 10.1057/Biosoc.2015.46 |
0.374 |
|
2016 |
Hansen H, Netherland J. Is the Prescription Opioid Epidemic a White Problem? American Journal of Public Health. 106: 2127-2129. PMID 27831792 DOI: 10.2105/Ajph.2016.303483 |
0.365 |
|
2016 |
Netherland J, Hansen HB. The War on Drugs That Wasn't: Wasted Whiteness, "Dirty Doctors," and Race in Media Coverage of Prescription Opioid Misuse. Culture, Medicine and Psychiatry. PMID 27272904 DOI: 10.1007/S11013-016-9496-5 |
0.382 |
|
2015 |
Netherland J, Hansen H. White Opioids: Pharmaceutical Race and the War on Drugs that Wasn’t (online publication) Biosocieties. DOI: 10.1057/Biosoc.2015 |
0.379 |
|
2011 |
Finkelstein R, Netherland J, Sylla L, Gourevitch MN, Cajina A, Cheever L. Policy implications of integrating buprenorphine/naloxone treatment and HIV care. Journal of Acquired Immune Deficiency Syndromes (1999). 56: S98-S104. PMID 21317602 DOI: 10.1097/Qai.0B013E31820A9A97 |
0.459 |
|
2011 |
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. Journal of Acquired Immune Deficiency Syndromes (1999). 56: S76-82. PMID 21317599 DOI: 10.1097/Qai.0B013E31820A9A66 |
0.368 |
|
2011 |
Weiss L, Egan JE, Botsko M, Netherland J, Fiellin DA, Finkelstein R. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. Journal of Acquired Immune Deficiency Syndromes (1999). 56: S7-13. PMID 21317598 DOI: 10.1097/Qai.0B013E3182097426 |
0.475 |
|
2011 |
Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, Altice FL. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. Journal of Acquired Immune Deficiency Syndromes (1999). 56: S68-75. PMID 21317597 DOI: 10.1097/Qai.0B013E31820A8226 |
0.409 |
|
2011 |
Egan JE, Netherland J, Gass J, Finkelstein R, Weiss L. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. Journal of Acquired Immune Deficiency Syndromes (1999). 56: S46-53. PMID 21317594 DOI: 10.1097/Qai.0B013E3182097561 |
0.451 |
|
2010 |
Egan JE, Casadonte P, Gartenmann T, Martin J, McCance-Katz EF, Netherland J, Renner JA, Weiss L, Saxon AJ, Fiellin DA. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. Journal of General Internal Medicine. 25: 936-41. PMID 20458550 DOI: 10.1007/S11606-010-1377-Y |
0.383 |
|
2009 |
Schackman BR, Dastur Z, Rubin DS, Berger J, Camhi E, Netherland J, Ni Q, Finkelstein R. Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. Aids Care. 21: 992-9. PMID 20024755 DOI: 10.1080/09540120802657506 |
0.381 |
|
2009 |
Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, Gourevitch MN, Renner JA, Sohler N, Sullivan LE, Weiss L, Fiellin DA. Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment. 36: 244-51. PMID 18715741 DOI: 10.1016/J.Jsat.2008.06.006 |
0.401 |
|
2006 |
Weiss L, French T, Waters M, Netherland J, Agins B, Finkelstein R. Adherence to HAART: perspectives from clients in treatment support programs. Psychology, Health & Medicine. 11: 155-70. PMID 17129905 DOI: 10.1080/13548500500159430 |
0.359 |
|
2002 |
Weiss L, Fabri A, McCoy K, Coffin P, Netherland J, Finkelstein R. A vulnerable population in a time of crisis: drug users and the attacks on the World Trade Center. Journal of Urban Health : Bulletin of the New York Academy of Medicine. 79: 392-403. PMID 12200508 DOI: 10.1093/Jurban/79.3.392 |
0.363 |
|
Show low-probability matches. |